RE:RE:RE:OBG clinical studyYes, some additional differences that can make this BG pill more successul in the clinical study vs. the Oatwell study.
On the eve of results from this BG study and some others, it befuddles me as to why there was a seller today from BMO who hit the bid by selling 48K shares. Being one seller is better than multiple sellers, perhaps one was selling for tax loss, to purchase a car, etc.
prophetoffacts wrote: CZO also monitors exercise which can reduce LDL. CZO also administers the beta glucan three times per day as opposed to the Oatwell study which administered it once in the morning. Administering beta glucan three times per day could help maintain stable supplies in the body.
CZO also administers up to double the daily intake of beta glucan per day and for 50% longer given the trial duration. What makes CZO's product unique is the purity, standardized, pharma-grade, and non-denatured nature. Just as PGX-YBG had interesting anti-inflammatory properties when purified, and had 5-times greater stimulatory properties of dectin-1 vs. spray-dried YBG, PGX-OBG could have differentiated properties. Anti-inflammatory properties are being measured in CZO's clinical trial by measureing c-reactive protein levels. Dr. Jean-Claude Tardif is interested in anti-inflammatory properties for heart disease with colchicine.
Ciao wrote: Great find!
If the BG pill has a similar effect as Oatwell powder than we could have better than the 12 - 15% LDL reduction reported for the Oatwell study considering;
1) higher dosage
2) longer study period
3) possible synergistic effects with statins
4) broader range of patients with different degrees of hypercholesterolemia
hoffbag wrote: Could be used as a reference for the Ceapro OBG study. Different approach but competitor.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146517/